Compare Abeona Therapeutics Inc (ABEO) vs Raytheon Technologies Corp (RTX) Price & Performance

ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.

Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.

RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.

The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.